Application

22:0 Trehalose has been used as an adjuvant for Chlamydia vaccine. It has also been used as a component in adjuvant DMT (dimethyldioctadecylammonium/monophosphoryl lipid A/trehalose 6,6′-dibehenate (DDA/MPL/TDB)) to prepare DMT liposome adjuvanted CTT3H (polyprotein) vaccine.

Biochem/physiol Actions

Incorporation of trehalose 6,6′-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets. It acts as an immunomodulator. 22:0 Trehalose is considered less toxic and an efficient vaccine adjuvant for tuberculosis.

General description

22:0 Trehalose is a bioactive glycolipid and an analog of mycobacterial cord factor.

Other Notes

For R&D use only. Not for drug, household, or other uses.

Packaging

5 mL Amber Glass Screw Cap Vial (890808P-5mg)

5 mL Amber Glass Screw Cap Vial (890808P-25mg)